Panel Discussion: Are We Measuring the Right Things? Defining Meaningful Flow Cytometry Readouts for Cell Therapy Development

• Identifying which attributes truly influence product quality and clinical performance
• Designing assay roadmaps that translate defined QTPPs and CQAs into fit for purpose analytical strategies
• Understanding where organisations still struggle to connect characterisation, potency, and clinical outcomes

Speakers:

Angela Holton

Executive Director

IOVANCE Biotherapeutics, Inc.

Jennifer Fox

Director, Analytical Sciences and Technology

AstraZeneca

Kevin Johnson

Director, Analytical Operations, Flow Cytometry Analytical Development

Kite Pharma Inc